Home >> Healthcare Administration >> Pharmaceuticals >> Food & Beverage >>

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H1 2013

Published: Feb-2013 | Format: PDF | Global Markets Direct | Number of pages: 39 | Code: MRS - 985

Global Markets Directs, 'Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD). 

Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Scope

A snapshot of the global therapeutic scenario for Non Alcoholic Fatty Liver Disease (NAFLD).
A review of the Non Alcoholic Fatty Liver Disease (NAFLD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline on the basis of route of administration and molecule type.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy

Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD).
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Non Alcoholic Fatty Liver Disease (NAFLD) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) 7
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics under Development by Companies 9
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics - Products under Development by Companies 14
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Development 16
F. Hoffmann-La Roche Ltd. 16
Phynova Group Ltd 17
Galmed International Ltd. 18
Connexios Life Sciences Pvt. Ltd. 19
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
PYN-22 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Aramchol - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
metreleptin - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
RO-5093151 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
oltipraz - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CNXFC-010 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
tranilast - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AMPK Activators For Fatty Liver Disease - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics - Drug Profile Updates 35
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics - Dormant Products 36
Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones 37
Featured News & Press Releases 37
Oct 31, 2012: Phenex Pharma Completes Phase I Studies With FXR-Agonist Px-102 37

Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Tables

Number of Products Under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2013 7
Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Comparative Analysis by Early Clinical Stage Development, H1 2013 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
F. Hoffmann-La Roche Ltd., H1 2013 16
Phynova Group Ltd, H1 2013 17
Galmed International Ltd., H1 2013 18
Connexios Life Sciences Pvt. Ltd., H1 2013 19
Assessment by Monotherapy Products, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 24
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics - Drug Profile Updates 35
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics - Dormant Products 36

List of Figures

Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H1 2013 7
Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Mid Clinical Stage Products, H1 2013 11
Early Clinical Stage Products, H1 2013 12
Discovery and Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 20
Assessment by Route of Administration, H1 2013 21
Assessment by Stage and Route of Administration, H1 2013 22
Assessment by Molecule Type, H1 2013 23
Assessment by Stage and Molecule Type, H1 2013 24


Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing